Show Notes
Skin is the body’s largest organ, and its health can reveal far more about aging and disease than what shows up in the mirror. In this episode of Tomorrow’s Cure from Mayo Clinic, host Cathy Wurzer talks with dermatologist and regenerative medicine expert Dr. Saranya Wyles of Mayo Clinic and biomedical engineer Dr. Adam Feinberg of Carnegie Mellon University about “SkinSpan” and the fast-moving world of 3D bioprinted skin.
They explore how layered, living skin models built from human cells and collagen are helping researchers study conditions like eczema, chronic wounds, burns, and age-related changes in skin structure and pigment. The episode also dives into Dr. Feinberg’s hands-on, open-source bioprinting workshops, where clinicians and scientists build their own high-performance bioprinters for a fraction of traditional costs. In turn, democratizing access to advanced regenerative tools and accelerating discovery worldwide. Through these collaborations, bioprinting moves from theory to practice, enabling more teams to test new therapies and customize tissue models for their patients.
The conversation further explores “zombie cells” (senescent cells), what they reveal about skin aging and inflammation, and how skin changes may influence whole-body health. Listeners will also hear about the ethical and practical questions that must be answered before bioprinted skin can reach routine patient care.
How to listen and stay connected:
Subscribe to Tomorrow’s Cure on your favorite podcast app and follow the show so you never miss an episode.
Get the latest health information from Mayo Clinic’s experts—subscribe to Mayo Clinic’s newsletter for free today: https://mayocl.in/3EcNPNc
Connect with Mayo Clinic:
Like Mayo Clinic on Facebook: https://www.facebook.com/mayoclinic/Follow
Mayo Clinic on Instagram: https://www.instagram.com/mayoclinic/Follow
Mayo Clinic on X (formerly Twitter): https://x.com/MayoClinicFollow
Mayo Clinic on Threads: https://www.threads.net/@mayoclinic
More from Tomorrow's Cure
How could Mayo Clinic’s Global AI Platform transform personalized care?
What if transplant patients could one day live free from lifelong anti-rejection drugs?
What happens when multiple sclerosis symptoms mask a different condition?
What if repairing damaged cartilage could be done in a single procedure? Using your own cells and the healing signals they need to recover?
What if the milk you are drinking could help fight cancer? In this episode of Tomorrow's Cure, we explore cholangiocarcinoma and a surprising new approach to targeting it using milk‑derived nanoparticles and precision aptamer‑based delivery. Host Lindsey Seavert is joined by surgical oncologist Dr. Rory Smoot and long‑term survivor and advocate Melinda Bachini to unpack why this cancer is so challenging, what symptoms and treatment paths patients typically face, and how emerging gene‑delivery platforms and AI‑driven discovery are opening new possibilities when standard therapies fall short. Through Melinda’s 16‑year survivorship story and Dr. Smoot’s lab work that literally starts with skim milk from the Mayo Clinic cafeteria, listeners hear how “chemical antibodies” called aptamers can act as molecular keys to deliver therapy directly to cholangiocarcinoma cells, and how computational tools are accelerating the search for new targets. Together, they discuss the emotional and practical realities of living at the edge of what medicine can do today, the expanding landscape of clinical trials, and why innovation in this rare cancer may ripple out to colon, lung and other hard‑to‑treat tumors.